ACTIVITY DESCRIPTION
Acute lymphoblastic leukemia (ALL) is the first hematologic neoplasm for which assessment of early response to therapy using measurable residual disease (MRD) has proven to be a fundamental tool for guiding therapy. It should be a key component in individualizing care to improve outcomes for patients. But MRD is a time point-dependent variable, with different time points signifying different prognosis for relapse. And MRD testing methods are variable across clinical practices, and it can be challenging to select the appropriate combination and sequence of therapy. Consequently, not all patients are provided with uniform care.
During Mastering MRD for Prognosis and Treatment in ALL, experts will discuss conducting MRD testing for patients with ALL according to the guideline-recommended schedule; evaluating the specimens needed for, and the pros and cons of, various methods for assessing MRD; predicting the risk of relapse based on MRD test results; and individualizing treatment based on MRD status to ensure patients at higher risk of relapse receive appropriate risk-adapted therapy.
This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.
Speakers
Jae H. Park, MD
Associate Attending Physician
Acting Chief, Cellular Therapeutic Service
Memorial Sloan Kettering Cancer Center
New York, NY
Jae Park, MD is Associate Attending Physician in the Division of Hematologic Oncology, Leukemia Service, a Director of Adult Acute Lymphoblastic Leukemia Program and the Acting Chief of Cellular Therapeutics Service at Memorial Sloan Kettering Cancer Center in New York City, New York. Dr. Park received his medical degree from the Johns Hopkins School of Medicine and completed an internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr. Park has written numerous peer-reviewed articles appearing in New England Journal of Medicine, Lancet, Nature Medicine, Science Translational Medicine, Blood, Cancer Discovery and Journal of Clinical Oncology. His research has been recognized and funded by the ASH, AACR, ASCO, Leukemia and Lymphoma Society, Geoffrey Beene Research Foundation, and NCCN. His research focus is to translate and establish novel targeted and immunotherapies for patients with hematologic malignancies. He is widely recognized as one of the world experts in the emerging field of CAR T cell therapies and ALL and is the leading principal investigator of several clinical trials in patients with ALL and CLL/NHL using CAR T, NK cell therapies, BiTEs, IDCs, targeted agents, and immunomodulators.
Rashmi Kanagal Shamanna, MD
Associate Professor, Department of Hematopathology
Director, Molecular Diagnostic Laboratory – Microarray
The University of Texas MD Anderson Cancer Center
Houston, TX
Dr. Rashmi Kanagal-Shamanna is a practicing board-certified Molecular Genetic Pathologist and Hematopathologist at The University of Texas MD Anderson Cancer Center. She is a tenured Associate Professor and Director of Clinical Molecular Diagnostic Laboratory (Microarray) in the dept. of Hematopathology.
Dr. Kanagal-Shamanna received her MD from St. John’s Medical College, Bangalore, India followed by a residency in Anatomic and Clinical Pathology at Henry Ford Hospital, Detroit, Michigan. She completed her fellowships in Hematopathology, Advanced Hematopathology as well as Molecular Genetic Pathology at The University of Texas M.D. Anderson Cancer Center. Dr. Kanagal-Shamanna’s clinical responsibilities include signing out bone marrow and lymph node biopsies, flow cytometry, and validation and reporting of clinical molecular assays. Her primary research interest is the application of novel tools for molecular profiling of hematological malignancies for prognosis and guiding therapy. She has ~200 highly cited peer-reviewed publications in her field and is a recipient of multiple intramural and extramural awards such as Institutional Research Grant, Ladies Leukemia League, RP Foundation and Leukemia SPORE career development award.
On the national front, Dr. Kanagal-Shamanna is the current President-Elect of the Cancer Genomics Consortium organization. She chairs the Professional Association Collaboration Committee for providing recommendations on appropriate utilization of genomic assays in patient care. She co-leads the Clinical Genome (ClinGen) resource’s Somatic Hematologic Malignancy Taskforce. She is an editorial board member for Cancer Genetics and an associate editor for Cancer Medicine.
Accreditation and Disclosure Information
TARGET AUDIENCE
This CE activity is intended for hematologic oncology clinicians, nurses, and pharmacists who provide care for individuals with acute lymphoblastic leukemia (ALL).
EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
- Conduct MRD testing according to the guideline-recommended schedule
- Evaluate the specimens needed for, and the pros and cons of, various methods of assessing MRD
- Predict the risk of relapse based on MRD test results
- Individualize treatment based on MRD status to ensure patients at higher risk of relapse receive appropriate risk-adapted therapy
AGENDA
- Welcome, introductions, overview
- Timing of MRD testing
- MRD testing methods
- Interpreting results of MRD tests
- Using results to guide treatment
- Summary of key points, post-test, evaluation, and final Q&A
ACCREDITATION, SUPPORT AND CREDIT
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
EACCME® Credit
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.33 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-112-H01-P
Type of Activity: Knowledge
SUPPORT STATEMENT
This activity is supported by educational funding provided by Amgen.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Jae H. Park, MD
Associate Attending Physician
Acting Chief, Cellular Therapeutic Service
Memorial Sloan Kettering Cancer Center,
New York, NY
Advisory Board/Consultant: Amgen, Allogene, Affyimmune, Artiva, Autolus, Bright Pharma, Bristol Myers Squibb, Curocell, GlaxoSmithKline, Incyte, Intellia, Kite Pharma, Kura Oncology, Minerva, Novartis, Pfizer, and Servier.
Research Grant: Fate Therapeutics, Genentech, and Takeda.
Planner/Presenter
Rashmi Kanagal Shamanna, MD
Associate Professor, Department of Hematopathology
Director, Molecular Diagnostic Laboratory – Microarray
The University of Texas MD Anderson Cancer Center
Houston, TX
Advisory Board/Consultant: Amgen, Inc.
Speakers’ Bureau: Amgen, Inc.
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Aptitude Health and Novartis
Speakers’ Bureau: Physicians’ Education Resource
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., do not have any relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURES OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org
For Physicians, if requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.